Pouillart P, Jouvet M, Palangie T, Garcia-Giralt E, Bretaudeau B, Dorval T, Asselain B
Ann Gastroenterol Hepatol (Paris). 1985 Feb-Mar;21(2):87-90.
In a serie of 759 patients treated for metastasized cancer of the breast, presence of an hepatic focus was observed in 29 percent of cases. Isolated hepatic metastases were found in 4 percent of cases while in 25 percent they were associated with other tissues. At the time of initial clinical staging, the difference between the hepatic metastases group and the other group stems from the much greater frequency of severity indices in the former group indicating a general and biological transformation of the metastatic tumor(s). At therapeutic staging, the slight effectiveness of medical therapies can be accounted for by the slight tolerance among patients with a secondary hepatic tumor(s). Lastly, it is interesting to note that progesterone receptor presence does not modify the prognosis in hepatic metastases cases.
在一组759例接受转移性乳腺癌治疗的患者中，29%的病例观察到肝脏病灶。4%的病例发现孤立性肝转移，而25%的病例中肝转移与其他组织相关。在初始临床分期时，肝转移组与另一组的差异源于前一组严重程度指标的频率高得多，这表明转移性肿瘤发生了普遍的生物学转变。在治疗分期时，药物治疗效果欠佳可归因于继发性肝肿瘤患者的耐受性较差。最后，值得注意的是，孕激素受体的存在并不会改变肝转移病例的预后。
